Comparison of outcome for holmium laser enucleation prostate and Rezum system in benign prostate hyperplasia: a matched pair analysis

1

Benign prostatic hyperplasia (BPH) is the leading cause of lower urinary tract symptoms in men over 50, often requiring surgical intervention when other treatments fail.
2

Holmium laser enucleation of the prostate (HoLEP) is considered the gold standard for BPH surgery, offering benefits like reduced blood loss and lower perioperative morbidity.
3

Rezum is a minimally invasive treatment for BPH that preserves sexual function and is effective for prostate volumes less than 80 g, with promising results for larger prostates.
4

This study aims to compare the efficacy and safety of Rezum and HoLEP in patients with symptomatic BPH, particularly those with prostate sizes over 50 g.
5

The study included 338 patients, assessing outcomes based on urinary flow metrics, symptom scores, and complications within three months post-surgery.

1